Undisclosed PRAM (SCN1A-targeting)
Dravet Syndrome
PreclinicalLead Optimization
Key Facts
About CAMP4 Therapeutics
CAMP4 Therapeutics is developing a new class of therapeutics that modulate gene expression by targeting the regulatory RNA network, a layer of biology upstream of proteins. The company's platform identifies druggable regRNA nodes to design oligonucleotide-based medicines that can precisely tune gene activity. With a focus on haploinsufficiency diseases, where increasing the output of a single healthy gene copy could provide therapeutic benefit, CAMP4 is building a pipeline with initial programs in CNS and metabolic disorders. The company is backed by leading life science investors and is advancing its lead programs toward clinical development.
View full company profileTherapeutic Areas
Other Dravet Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| Zorevunersen (STK-001) | Stoke Therapeutics | Phase 3 |